News

The study will evaluate the safety and plasma pharmacokinetics of multiple doses of RG3039, an orally bioavailable small molecule inhibitor of an RNA processing enzyme called DcpS, in

The two identical 52-week, double-blind, randomised, placebo-controlled trials with matching twice-daily 150mg dosing, inclusion criteria and endpoints enrolled a total of 970 patients in 20 countries. The annual

As part of the agreement, Galderma will carry on the ongoing NVC-422 clinical development program for impetigo and NovaBay will receive double-digit royalties on net sales of products.

The once-daily investigational medicine FF/VI is used to treat chronic obstructive pulmonary disease (COPD). The Marketing Authorisation Application for FF/VI for COPD and asthma has also been validated

Teijin Pharma is planning to begin phase I clinical trials for ADC3680 in Japan in April 2013, while Pulmagen Therapeutics has already begun phase II clinical trials for

The company has already purchased land and is planning to begin the work from November 2012. The company will produce hi-tech Active Pharma Ingredients (APIs), specialty enzymes for

As part of the settlement, Abaxis will receive $17.25m from Cepheid and withdraw all pending litigation claims. Abaxis CEO and chairman Clint Severson said the agreement will allow

The added enhancements are available across all MedeAnalytics solutions and require no upgrades or installations to access them, according to the company. MedeAnalytic product management vice president Christian

RayBiotech will leverage the reagents and technologies to expand its antibody-based products and services platforms. The financial terms of the agreement were kept confidential. Commenting on the license,